Cochrane · systematic review · CD005128
Interventions for preventing and treating kidney disease in IgA vasculitis
Hahn, D, Hodson, EM, Craig, JC · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 28.6%Moderate 4 · 57.1%High 1 · 14.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyPrednisone versus placebo or supportive treatment for preventing persistent kidney disease in patients with IgAV (Henoch‐ Schönlein Purpura)
Population: patients with IgAV
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Persistent kidney disease at any time after treatment Prednisone vs placebo or supportive treatment | RR 0.74 [0.42, 1.32] | 5 studies · 746 participants | Moderate Downgraded: risk of bias |
Children with any continuing kidney disease at 3 months Prednisone vs placebo or supportive treatment | RR 0.83 [0.46, 1.52] | 4 studies · 655 participants | Moderate Downgraded: risk of bias, imprecision |
Children with any continuing kidney disease at 6 months Prednisone vs placebo or supportive treatment | RR 0.51 [0.24, 1.11] | 3 studies · 379 participants | Moderate Downgraded: risk of bias, imprecision |
Children with any continuing kidney disease at 12 months Prednisone vs placebo or supportive treatment | RR 1.06 [0.38, 2.91] | 3 studies · 455 participants | Low Downgraded: risk of bias, imprecision |
Any continuing kidney disease at 3 months (study with high risk of bias excluded) Prednisone vs placebo or supportive treatment | RR 0.98 [0.7, 1.36] | 3 studies · 487 participants | High |
Any continuing kidney disease at 12 months (study with high risk of bias excluded) Prednisone vs placebo or supportive treatment | RR 1.39 [0.75, 2.59] | 2 studies · 287 participants | Moderate Downgraded: imprecision |
Number developing severe kidney disease Prednisone vs placebo or supportive treatment | RR 1.58 [0.42, 6] | 2 studies · 418 participants | Low Downgraded: imprecision |
Prednisone versus placebo or supportive treatment for preventing persistent kidney disease in patients with Henoch‐Schönlein Purpura (HSP)
Population: patients with HSP
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Persistent kidney disease at any time after treatment Prednisone vs placebo or supportive treatment | RR 0.74 [0.42, 1.32] | 5 studies · 746 participants | Moderate Downgraded: risk of bias |
Number of children with any continuing kidney disease at 3 months Prednisone vs placebo or supportive treatment | RR 0.83 [0.46, 1.52] | 4 studies · 655 participants | Moderate Downgraded: risk of bias, imprecision |
Number of children with any continuing kidney disease at 6 months Prednisone vs placebo or supportive treatment | RR 0.51 [0.24, 1.11] | 3 studies · 379 participants | Moderate Downgraded: risk of bias, imprecision |
Number of children with any continuing kidney disease at 12 months Prednisone vs placebo or supportive treatment | RR 1.06 [0.38, 2.91] | 3 studies · 455 participants | Low Downgraded: risk of bias, imprecision |
Any continuing kidney disease at 3 months (study with high risk of bias excluded) Prednisone vs placebo or supportive treatment | RR 0.98 [0.7, 1.36] | 3 studies · 487 participants | High |
Any continuing kidney disease at 12 months (study with high risk of bias excluded) Prednisone vs placebo or supportive treatment | RR 1.39 [0.75, 2.59] | 2 studies · 287 participants | Moderate Downgraded: imprecision |
Number developing severe kidney disease Prednisone vs placebo or supportive treatment | RR 1.58 [0.42, 6] | 2 studies · 418 participants | Low Downgraded: imprecision |
Prednisone summary of findings
Population: patients with HSP
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Persistent kidney disease at any time after treatment ( | RR 0.73 [0.43, 1.24] | 5 studies · 789 participants | Moderate Downgraded: risk of bias, imprecision |
Number of children with continuing kidney disease at different time points ‐ Three months ( | RR 0.82 [0.45, 1.5] | 4 studies · 636 participants | Moderate Downgraded: risk of bias, imprecision |
Number of children with continuing kidney disease at different time points ‐ Six months ( | RR 0.51 [0.24, 1.11] | 3 studies · 379 participants | Moderate Downgraded: risk of bias, imprecision |
Number of children with continuing kidney disease at different time points ‐ Twelve months ( | RR 1.02 [0.4, 2.62] | 3 studies · 498 participants | Moderate Downgraded: risk of bias, imprecision |
Continuing kidney disease at different time points, study with high risk of bias excluded ‐ Three months ( | RR 0.95 [0.66, 1.36] | 3 studies · 468 participants | Moderate Downgraded: risk of bias, imprecision |
Continuing kidney disease at different time points, study with high risk of bias excluded ‐ Twelve months ( | RR 1.28 [0.7, 2.32] | 2 studies · 330 participants | Moderate Downgraded: risk of bias, imprecision |
Number developing severe kidney disease ( | RR 1.92 [0.57, 6.5] | 2 studies · 461 participants | Low Downgraded: risk of bias, imprecision |
Antiplatelet summary of findings
Population: patients with HSP
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Kidney disease at any time ‐ Dipyridamole +/‐ cyproheptadine in children without kidney disease at entry ( | RR 1.16 [0.46, 2.95] | 2 studies · 101 participants | Low Downgraded: risk of bias, imprecision |
Kidney disease at any time ‐ Dipyridamole +/‐ cyproheptadine in children with kidney disease at entry ( | RR 0.92 [0.23, 3.72] | 1 study · 19 participants | Low Downgraded: risk of bias, imprecision |
Kidney disease at any time ‐ Aspirin compared with supportive treatment | RR 0.14 [0.01, 2.42] | 1 study · 18 participants | Low Downgraded: risk of bias, imprecision |
Heparin summary of findings
Population: patients with HSP
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Type of kidney disease at 3 months or more after onset or relapse | RR 0.15 [0.03, 0.67] | 1 study · 684 participants | Low Downgraded: risk of bias |
Cyclophosphamide summary of findings
Population: patients with HSP
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Persistent kidney disease ( | RR 1.07 [0.65, 1.78] | 1 study · 56 participants | Moderate Downgraded: risk of bias |
Persistent severe kidney disease ( | RR 0.88 [0.37, 2.09] | 1 study · 56 participants | Moderate Downgraded: risk of bias |
Cyclosporin summary of findings
Population: patients with HSP
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number without remission at last | RR 0.39 [0.14, 1.06] | 1 study · 19 participants | Low Downgraded: risk of bias |